DBV Technologies (NASDAQ:DBVT) Now Covered by StockNews.com

Analysts at StockNews.com initiated coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report released on Sunday. The brokerage set a “hold” rating on the stock.

Other equities analysts also recently issued reports about the company. JMP Securities reiterated a “market outperform” rating and set a $5.00 target price on shares of DBV Technologies in a research report on Tuesday, September 24th. HC Wainwright restated a “buy” rating and set a $5.00 price objective on shares of DBV Technologies in a report on Thursday, August 1st.

DBV Technologies Stock Performance

Shares of NASDAQ:DBVT opened at $0.70 on Friday. DBV Technologies has a one year low of $0.50 and a one year high of $2.40. The stock has a market cap of $67.45 million, a PE ratio of -0.83 and a beta of 0.67. The business’s fifty day moving average price is $0.81 and its two-hundred day moving average price is $1.00.

DBV Technologies (NASDAQ:DBVT) last posted its quarterly earnings data on Tuesday, July 30th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.08). DBV Technologies had a negative return on equity of 74.41% and a negative net margin of 638.21%. The company had revenue of $1.16 million for the quarter, compared to analysts’ expectations of $1.42 million. During the same quarter in the prior year, the business posted ($0.26) EPS. As a group, equities research analysts predict that DBV Technologies will post -1.43 earnings per share for the current fiscal year.

Institutional Trading of DBV Technologies

A hedge fund recently raised its stake in DBV Technologies stock. Yiheng Capital Management L.P. boosted its holdings in DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,568,909 shares of the company’s stock after purchasing an additional 327,345 shares during the period. DBV Technologies comprises 0.2% of Yiheng Capital Management L.P.’s portfolio, making the stock its 15th largest position. Yiheng Capital Management L.P. owned 2.89% of DBV Technologies worth $4,172,000 as of its most recent SEC filing. 71.74% of the stock is owned by hedge funds and other institutional investors.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.